Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia. Issue 1 (7th January 2022)

• Record Type: Journal Article
• Authors: Rizzuto, Giuliana; Leoncin, Matteo; Imbergamo, Silvia; Taurino, Daniela; Mico, Maria Caterina; Tosi, Manuela; Michelato, Anna; Buklijas, Ksenija; Spinelli, Orietta; Lussana, Federico; Lessi, Federica; Pizzi, Marco; Bonaldi, Laura; Binotto, Gianni; Rambaldi, Alessandro; Gurrieri, Carmela
• Is Part Of: Clinical case reports. Volume 10:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-07
• Subjects: acute B‐lymphoblastic leukemia -- case report -- myeloid sarcoma -- PCM1‐JAK2 myeloproliferative neoplasm -- ruxolitinib; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.5212
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1 ‐ JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2 that renders this disease potentially sensitive to ruxolitinib. Here, we report an interesting case of PCM1 ‐ JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor ALL. Abstract : The identification of a specific molecular marker offered the possibility to monitor the depth of remission after transplant and to start an early preemptive therapy with ruxolitinib as soon as any evidence of disease reappraisal was documented.